<div id="readability-page-1"><div><p>Grand Pharmaceutical Group (SEHK:512) has had a busy stretch, securing China approval to commercialize eye treatment GPN01768, advancing migraine drug GPN01020 into Phase II trials, reporting full year 2025 earnings, and updating its dividend.</p> <p>See our latest analysis for Grand Pharmaceutical Group.</p> <p>The recent China approvals for GPN01768 and the Phase II go ahead for GPN01020 come as the share price trades at HK$7.22, with a 7 day share price return of 6.49% but a 90 day share price return showing a 7.44% decline, while the 3 year total shareholder return of 76.97% points to stronger longer term momentum.</p> <p>If you are interested in how other healthcare names are shaping up around new therapies and clinical progress, it is worth scanning 125 healthcare AI stocks</p> <p>With the share price at HK$7.22, a 68% intrinsic discount estimate and a sizeable gap to the HK$11.25 analyst target, investors now have to ask: is this a genuine mispricing, or is the market already baking in future growth?</p> <h2>Preferred P/E of 20.4x: Is it justified?</h2> <p>Grand Pharmaceutical Group trades on a P/E of 20.4x, which screens as good value against both its own estimated fair P/E and the peer average, even after a weaker share price over the past 90 days.</p> <p>The P/E ratio compares the current share price with earnings per share and, for a pharmaceutical business like Grand Pharmaceutical Group, it reflects what investors are willing to pay for each unit of current earnings. A higher P/E can suggest the market is factoring in stronger future profitability, while a lower P/E can indicate more muted expectations or higher perceived risk.</p> <p>Here, the stock is assessed as good value relative to an estimated fair P/E of 25.1x, a level the market could move towards if earnings unfold in line with expectations. It is also described as good value versus the peer average P/E of 21.6x, even though it is considered expensive versus the broader Hong Kong Pharmaceuticals industry average of 15.4x, which points to investors assigning a premium for this specific earnings profile.</p> <p>Explore the SWS fair ratio for Grand Pharmaceutical Group</p> <p><strong>Result: Price-to-earnings of 20.4x (UNDERVALUED)</strong></p> <p>However, there are clear risks, including any setbacks in clinical trials or regulatory approvals, and the possibility that China-focused revenue concentrations limit flexibility if conditions change.</p> <p>Find out about the key risks to this Grand Pharmaceutical Group narrative.</p> <h2>Another view using the SWS DCF model</h2> <p>While the P/E of 20.4x points to what screens as good value, the SWS DCF model presents a different perspective. It shows an estimated future cash flow value of HK$22.44 per share versus a current price of HK$7.22, implying a very wide valuation gap that could reflect risk as much as opportunity.</p> <p>Look into how the SWS DCF model arrives at its fair value.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/639e7f90-1c43-4e2e-adb8-074b9a24cc0b/chart/dcf/query-ZGF0ZT0yMDI2LTA0LTA1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/639e7f90-1c43-4e2e-adb8-074b9a24cc0b/chart/dcf/query-ZGF0ZT0yMDI2LTA0LTA1"/><figcaption>512 Discounted Cash Flow as at Apr 2026</figcaption></figure><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Grand Pharmaceutical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 245 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2>Next Steps</h2> <p>The mix of potential upside and clear risks here is hard to ignore. Act while the information is fresh and form your own view using 3 key rewards and 1 important warning sign</p> <h2>Looking for more investment ideas?</h2> <p>If this opportunity has your attention, do not stop here. A broader watchlist can help you spot strong setups early and avoid narrow decisions.</p> <ul> <li>Hunt for quality at a discount by checking companies highlighted in 245 high quality undervalued stocks.</li> <li>Prioritize resilience by reviewing stocks in the 277 resilient stocks with low risk scores.</li> <li>Target staying power and liquidity by assessing ideas in the 228 elite penny stocks with strong financials.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

00512

513700

159992

<p>Grand Pharmaceutical Group (SEHK:512) has received China approval for eye treatment GPN01768 and advanced migraine drug GPN01020 to Phase II trials. The stock trades at HK$7.22, with a 6.49% return over the past week but a 7.44% decline over 90 days. The P/E ratio of 20.4x suggests good value compared to its fair P/E of 25.1x and peer average of 21.6x, despite risks from clinical trials and revenue concentration. A DCF model estimates a future cash flow value of HK$22.44 per share, indicating a significant valuation gap.</p>

Simplywall

GRANDPHARMA

Penghua CSI HK Connect Health Care Composite ETF

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng Health Care ETF(QDII)

China Merchants CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

HUADONG MEDICINE

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

GRAND HOLDING

China Universal CNI HK Connect Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

E Fund CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

Minsheng Royal CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Guotai CSI Bio-medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC CSI All Share Health Care Devices ETF

Assessing Grand Pharmaceutical Group (SEHK:512) Valuation After China Drug Approvals And Earnings Update